Early and Mid-Term Outcomes of Percutaneous Mitral Valve Repair with the MitraClip®: Comparative Analysis of Different EuroSCORE Strata.

Aims: Compare mid-term outcomes. after MitraClip (R) implantation for severe mitral regurgitation (MR) in patients categorised in different logistic EuroSCORE (LES) groups.Methods and results: MitraClip was implanted in 85 patients (78 6 years, 48 men [56.5%]) with severe symptomatic MR. Baseline characteristics, perioperative results, mid-term survival, major adverse cerebrovascular and cardiac events (MACCE), and re-hospitalisation were compared in patients with LES <20% (n=30) and >= 20% (n=55). Overall LES was 24 +/- 12 (range 2.5-56.3) and STS-score 12 +/- 7 (range 1.2-31.2). Overall procedural success rate was 96.5% with an in-hospital mortality rate of 3.5%. Echocardiographic and clinical follow-up confirmed similar mean transmitral pressure gradient (p=0.13), MR degree (p=0.48), and NYHA Class (p=0.93). Estimated six-month survival and freedom from composite endpoint was 80.7%/77.1% in LES >= 220% and 90.8/86.6% in LES<20% group, respectively (p=0.014; p=0.018). Multivariate analysis determined LES >= 20% (OR=8.1; 95% CI 1.002-65.186), mean transmitral gradient after intervention (OR 2.5; 95% CI 1.267-5.131) and residual MR (OR=5.1; 95% Cl 1.464-17.946) as predictors for overall mortality.Conclusions: LES is a good predictor of perioperative results, and follow-up adverse outcomes after MitraClip implantation are significantly influenced by the preoperative risk profile. The presence of residual MR immediately after MitraClip therapy can exacerbate the occurrence of MACCE.